Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123139) titled 'Establishment of a new method for blood concentration of camrelizumaband association of PD-1 gene polymorphism with drug efficacy and safetyin patients with head and neck squamous cell carcinoma' on April 22.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Condition:
Head and Neck Squamous Cell Carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-05
Target Sample Size: Camrelizumab trial group (exposed group):100;
Countries of Recruitment:
China
To know mo...